상세 보기
Ozonated Sunflower Oil (OSO) alleviates inflammatory responses in oxazolone-induced atopic dermatitis (AD)-like mice and LPS- treated RAW 264.7 cells
- Kim, Su-Young;
- Lee, Jung Ok;
- Lee, Sue;
- Heo, Jihye;
- Cho, Kyung-Hyun;
- ... Yoo, Kwang-Ho;
- ... Kim, Beom Joon;
- 외 1명
WEB OF SCIENCE
13SCOPUS
12초록
Ozone, a highly reactive oxidant molecule, is widely used as a complementary therapy for various skin diseases, including wound healing, pressure ulcers, diabetic foot, and infections. However, there is limited research on the effectiveness of ozone for atopic dermatitis (AD). Ozonated sunflower oil (OSO) is an active ingredient obtained from partially ozonated sunflower oil (SO). OSO markedly reduced the LPS-induced increase in IL-1β and nitric oxide (NO) levels in RAW 264.7 mouse macrophage cells. Oxazolone (OXZ) was applied to hairless mice to induce AD-like skin symptoms and immune response. OSO significantly alleviated the OXZ-induced increases in the number of infiltrating mast cells, epidermal thickness, AD symptoms, thymic stromal lymphopoietin (TSLP), and filaggrin, as well as the serum levels of NO, IgE, IL-1β, and TNF-α. Furthermore, OSO inhibited the IL-4/STAT3/MAPK pathway and the expression of NF-κB. Our results suggest that OSO treatment could relieve AD-mediated skin damage through its anti-inflammatory and antioxidant activities. Therefore, it can be used as a therapeutic agent against AD-related skin diseases.
키워드
- 제목
- Ozonated Sunflower Oil (OSO) alleviates inflammatory responses in oxazolone-induced atopic dermatitis (AD)-like mice and LPS- treated RAW 264.7 cells
- 제목 (타언어)
- Ozonated Sunflower Oil (OSO) Alleviates Inflammatory Responses in Oxazolone-Induced Atopic Dermatitis (AD)-Like Mice and LPS-Treated RAW 264.7 Cells
- 저자
- Kim, Su-Young; Lee, Jung Ok; Lee, Sue; Heo, Jihye; Cho, Kyung-Hyun; Bahuguna, Ashutosh; Yoo, Kwang-Ho; Kim, Beom Joon
- 발행일
- 2024-04
- 유형
- Article
- 권
- 34
- 호
- 4
- 페이지
- 1 ~ 10
- 언어
- ENG
- 출판사
- 한국미생물·생명공학회
- 발행국가
- 대한민국
- 분량
- 10 페이지
- ISSN
- E 1738-8872
P 1017-7825